A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
Research output: Contribution to journal › Journal article › Research › peer-review
ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.
Original language | English |
---|---|
Journal | Infection: A Journal of Infectious Diseases |
Volume | 42 |
Issue number | 4 |
Pages (from-to) | 757-762 |
Number of pages | 6 |
ISSN | 0300-8126 |
DOIs | |
Publication status | Published - Aug 2014 |
- Adenine, Adult, Anti-HIV Agents, Cohort Studies, Data Collection, Deoxycytidine, Drug Combinations, Drug Utilization, Europe, Female, HIV Infections, Humans, Male, Organophosphonates, Oxazines, Prospective Studies
Research areas
ID: 137311036